GPG Ventures
5
15M
4
0.20
1
- Areas of investment
Summary
Among the most popular portfolio startups of the fund, we may highlight Hypergiant Sensory Sciences, Lantern Pharma. The fund has no exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Alternative Medicine, Pharmaceutical.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the GPG Ventures, startups are often financed by Health Wildcatters, Green Park & Golf Ventures. The meaningful sponsors for the fund in investment in the same round are Chris Rhodes, Capital Factory, Bios Partners.
Besides them, we counted 1 critical employee of this fund in our database.
The important activity for fund was in 2018. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 1 - 5 millions dollars.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 0
- Exits
- 1
- Follow on index
- 0.20
- Investments by industry
- Artificial Intelligence (3)
- Computer (2)
- Software (2)
- Therapeutics (2)
- Biotechnology (2) Show 2 more
- Investments by region
-
- United States (5)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Recuro Health | 11 Apr 2023 | Health Care | Early Stage Venture | 47M | United States, Texas, Richardson |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.